Results 231 to 240 of about 23,280 (257)

[Sitagliptin].

Revue de l'infirmiere, 2008
J Matthes, M Faust
openaire   +3 more sources

Sitagliptin

Reactions Weekly, 2018
openaire   +2 more sources

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

The Lancet Diabetes and Endocrinology, 2017
Ah-Ren Bo, L. Masmiquel, H. Kumar, M. Sargin, J. D. Karsbøl, S. H. Jacobsen, F. Chow   +6 more
semanticscholar   +1 more source

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Diabetologia, 2006
D Williams-Herman
exaly  

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

Diabetes Therapy, 2013
Samuel S Engel, Barry J Goldstein, Gregory T Golm   +2 more
exaly  

Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

Diabetes Care, 2007
Jeremy S Johnson, Barry J Goldstein, Mark N. Feinglos   +2 more
exaly  

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial

Diabetes Care, 2013
Julio Rosenstock, Guntram Schernthaner, Gary Meininger   +2 more
exaly  

Sitagliptin: A Review in Type 2 Diabetes

Drugs, 2017
Lesley J Scott
exaly  

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

Diabetologia, 2013
Fernando Javier Lavalle-González, A Januszewicz, G Meininger   +2 more
exaly  

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

Diabetes Research and Clinical Practice, 2009
Wenying Yang, Son Ho-young
exaly